IDEAS home Printed from https://ideas.repec.org/a/wly/hlthec/v25y2016is1p179-192.html
   My bibliography  Save this article

HTA Implementation Roadmap in Central and Eastern European Countries

Author

Listed:
  • Zoltán Kaló
  • Adrian Gheorghe
  • Mirjana Huic
  • Marcell Csanádi
  • Finn Boerlum Kristensen

Abstract

The opportunity cost of inappropriate health policy decisions is greater in Central and Eastern European (CEE) compared with Western European (WE) countries because of poorer population health and more limited healthcare resources. Application of health technology assessment (HTA) prior to healthcare financing decisions can improve the allocative efficiency of scarce resources. However, few CEE countries have a clear roadmap for HTA implementation. Examples from high‐income countries may not be directly relevant, as CEE countries cannot allocate so much financial and human resources for substantiating policy decisions with evidence. Our objective was to describe the main HTA implementation scenarios in CEE countries and summarize the most important questions related to capacity building, financing HTA research, process and organizational structure for HTA, standardization of HTA methodology, use of local data, scope of mandatory HTA, decision criteria, and international collaboration in HTA. Although HTA implementation strategies from the region can be relevant examples for other CEE countries with similar cultural environment and economic status, HTA roadmaps are not still fully transferable without taking into account country‐specific aspects, such as country size, gross domestic product per capita, major social values, public health priorities, and fragmentation of healthcare financing. Copyright © 2016 John Wiley & Sons, Ltd.

Suggested Citation

  • Zoltán Kaló & Adrian Gheorghe & Mirjana Huic & Marcell Csanádi & Finn Boerlum Kristensen, 2016. "HTA Implementation Roadmap in Central and Eastern European Countries," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 179-192, February.
  • Handle: RePEc:wly:hlthec:v:25:y:2016:i:s1:p:179-192
    DOI: 10.1002/hec.3298
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hec.3298
    Download Restriction: no

    File URL: https://libkey.io/10.1002/hec.3298?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Gibis, Bernhard & Artiles, Justo & Corabian, Paula & Meiesaar, Kersti & Koppel, Agris & Jacobs, Philip & Serrano, Pedro & Menon, Devidas, 2001. "Application of strengths, weaknesses, opportunities and threats analysis in the development of a health technology assessment program," Health Policy, Elsevier, vol. 58(1), pages 27-35, October.
    2. Iskrov, Georgi & Miteva-Katrandzhieva, Tsonka & Stefanov, Rumen, 2012. "Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria," Health Policy, Elsevier, vol. 108(1), pages 10-18.
    3. Imre Boncz & Réka Vajda & István Ágoston & Dóra Endrei & Andor Sebestyén, 2014. "Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 137-141, May.
    4. Marco Liverani & Benjamin Hawkins & Justin O Parkhurst, 2013. "Political and Institutional Influences on the Use of Evidence in Public Health Policy. A Systematic Review," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-9, October.
    5. Mihajlo Jakovljevic, 2013. "Resource allocation strategies in Southeastern European health policy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(2), pages 153-159, April.
    6. Allen, Nicola & Pichler, Franz & Wang, Tina & Patel, Sundip & Salek, Sam, 2013. "Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems," Health Policy, Elsevier, vol. 113(3), pages 305-312.
    7. Lopert, Ruth & Ruiz, Francis & Chalkidou, Kalipso, 2013. "Applying rapid ‘de-facto’ HTA in resource-limited settings: Experience from Romania," Health Policy, Elsevier, vol. 112(3), pages 202-208.
    8. Nicod, Elena & Kanavos, Panos, 2012. "Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions," Health Policy, Elsevier, vol. 108(2), pages 167-177.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    2. Catherine Pitt & Anna Vassall & Yot Teerawattananon & Ulla K. Griffiths & Lorna Guinness & Damian Walker & Nicola Foster & Kara Hanson, 2016. "Foreword: Health Economic Evaluations in Low‐ and Middle‐income Countries: Methodological Issues and Challenges for Priority Setting," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 1-5, February.
    3. Matthew Kennedy-Martin & Bernhard Slaap & Michael Herdman & Mandy Reenen & Tessa Kennedy-Martin & Wolfgang Greiner & Jan Busschbach & Kristina S. Boye, 2020. "Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1245-1257, November.
    4. Sandor Kovács & Zoltán Kaló & Rita Daubner‐Bendes & Katarzyna Kolasa & Rok Hren & Tomas Tesar & Vivian Reckers‐Droog & Werner Brouwer & Carlo Federici & Mike Drummond & Antal Tamás Zemplényi, 2022. "Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 195-206, September.
    5. García-Mochón, Leticia & Espín Balbino, Jaime & Olry de Labry Lima, Antonio & Caro Martinez, Araceli & Martin Ruiz, Eva & Pérez Velasco, Román, 2019. "HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey," Health Policy, Elsevier, vol. 123(2), pages 182-190.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Pejcic, Ana V. & Iskrov, Georgi & Jakovljevic, Mihajlo Michael & Stefanov, Rumen, 2018. "Access to orphan drugs – comparison across Balkan countries," Health Policy, Elsevier, vol. 122(6), pages 583-589.
    2. László Gulácsi & Alexandru Rotar & Maciej Niewada & Olga Löblová & Fanni Rencz & Guenka Petrova & Imre Boncz & Niek Klazinga, 2014. "Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 13-25, May.
    3. Visintin, Erica & Tinelli, Michela & Kanavos, Panos, 2019. "Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries," Health Policy, Elsevier, vol. 123(2), pages 118-129.
    4. Mihajlo Jakovljevic & Mirjana Jovanovic & Nemanja Rancic & Benjamin Vyssoki & Natasa Djordjevic, 2014. "LAT Software Induced Savings on Medical Costs of Alcohol Addicts' Care - Results from a Matched-Pairs Case-Control Study," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-8, November.
    5. Astrida Miceikienė & Laima Skauronė & Ričardas Krikštolaitis, 2021. "Assessment of the Financial Autonomy of Rural Municipalities," Economies, MDPI, vol. 9(3), pages 1-21, July.
    6. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    7. Cyr, Pascale Renée & Jain, Vageesh & Chalkidou, Kalipso & Ottersen, Trygve & Gopinathan, Unni, 2021. "Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content," Health Policy, Elsevier, vol. 125(8), pages 1054-1064.
    8. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    9. Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
    10. Lilla Horváth & Imre Boncz & Zsuzsanna Kívés & Gergely Fehér & Noémi Németh & Fanni Luca Kajos & Katalin Biró & Krisztina Fendrik & Katalin Koltai & Gábor Késmárky & Dóra Endrei, 2023. "Disease-Specific Quality of Life among Patients with Peripheral Artery Disease in Hungary," IJERPH, MDPI, vol. 20(4), pages 1-14, February.
    11. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
    12. João Vasco Santos & Mariana Lobo & Rui Manuel Neiva & João Viana & Júlio Souza & Cláudia Camila Dias & Jonathan Cylus & Walter Ricciardi & Alberto Freitas, 2020. "European Union state of health from 1990 to 2017: time trends and its enlargements’ effects," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 65(2), pages 175-186, March.
    13. Weldon, Isaac & Parkhurst, Justin, 2022. "Governing evidence use in the nutrition policy process: evidence and lessons from the 2020 Canada food guide," LSE Research Online Documents on Economics 112430, London School of Economics and Political Science, LSE Library.
    14. Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.
    15. Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
    16. Salas-Vega, Sebastian & Bertling, Annika & Mossialos, Elias, 2016. "A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK," Health Policy, Elsevier, vol. 120(10), pages 1104-1114.
    17. Núria Homedes & Antonio Ugalde, 2016. "Health and Ethical Consequences of Outsourcing Pivotal Clinical Trials to Latin America: A Cross-Sectional, Descriptive Study," PLOS ONE, Public Library of Science, vol. 11(6), pages 1-17, June.
    18. Tresa, Eni & Czabanowska, Katarzyna & Clemens, Timo & Brand, Helmut & Babich, Suzanne M. & Bjegovic-Mikanovic, Vesna & Burazeri, Genc, 2022. "Europeanization of health policy in post-communist European societies: Comparison of six Western Balkan countries," Health Policy, Elsevier, vol. 126(8), pages 816-823.
    19. Mihajlo Jakovljevic & Elena Potapchik & Larisa Popovich & Debasis Barik & Thomas E. Getzen, 2017. "Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025," Health Economics, John Wiley & Sons, Ltd., vol. 26(7), pages 844-852, July.
    20. Victoria Serra-Sastre & Simona Bianchi & Jorge Mestre-Ferrandiz & Phill O’Neill, 2021. "Does NICE influence the adoption and uptake of generics in the UK?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(2), pages 229-242, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:25:y:2016:i:s1:p:179-192. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.